Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles

  • Withdrawn
  • Review
  • Intervention

Authors

  • Lars W Westergaard,

    1. Odense University Hospital, Department of Obstetrics and Gynecology, Odense C, Denmark
    Search for more papers by this author
  • Patrick MM Bossuyt,

    1. Academic Medical Center, University of Amsterdam, Department of Clinical Epidemiology and Biostatistics, Amsterdam, Netherlands
    Search for more papers by this author
  • Fulco Van der Veen,

    1. Academic Medical Center, Center for Reproductive Medicine - H4-205, Department of Obstetrics & Gynaecology, Amsterdam, Netherlands
    Search for more papers by this author
  • Madelon van Wely

    Corresponding author
    1. University of Amsterdam, Academic Medical Centre, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands
    • Madelon van Wely, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, University of Amsterdam, Academic Medical Centre, Center Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands. m.vanwely@amc.uva.nl.

    Search for more papers by this author

Reason for withdrawal from publication

An amendment was made to this review on 17 February 2003. In the trial of Diedrich (2002) the rFSH was Follitropin Alpha (Gonal-F, Serono) and not Follitropin Beta (Puregon, Organon) as was stated in the original review. This error was corrected.